Molecular structure of Andrographolide, CAS Number: 5508-58-7
Andrographolide (CAS 5508-58-7)
See product citations (7)
Alternate Names:
Andro; Andrographis
Application:
Andrographolide is an irreversible antagonist of NFκB and AP-1
CAS Number:
5508-58-7
Purity:
≥98%
Molecular Weight:
350.45
Molecular Formula:
C20H30O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Andrographolide is extensively utilized in biochemical research due to its role as an inhibitor of NF-kappaB, a protein complex that controls transcription of DNA, cytokine production, and cell survival. This activity is for studies on inflammatory processes and immune response, where Andrographolide can modulate the expression of genes involved in inflammation. Research involving Andrographolide frequently focuses on its impact on cellular signaling pathways and its ability to modulate immune cell behavior, which is fundamental for understanding autoimmune diseases and immune system regulation. Additionally, Andrographolide is used in studies investigating oxidative stress and the protective effects it may have against cellular damage caused by free radicals. This compound also plays a role in examining the mechanisms of apoptosis, contributing to a broader understanding of cell lifecycle regulation.
Andrographolide (CAS 5508-58-7) References
- Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. | Yu, BC., et al. 2003. Planta Med. 69: 1075-9. PMID: 14750020
- Andrographolide suppresses endothelial cell apoptosis via activation of phosphatidyl inositol-3-kinase/Akt pathway. | Chen, JH., et al. 2004. Biochem Pharmacol. 67: 1337-45. PMID: 15013849
- Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. | Xia, YF., et al. 2004. J Immunol. 173: 4207-17. PMID: 15356172
- Andrographolide contributes to the attenuation of cardiac hypertrophy by suppressing endoplasmic reticulum stress. | Tian, Q., et al. 2023. Pharm Biol. 61: 61-68. PMID: 36548192
- Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 liver cancer cells. | Neamatallah, T., et al. 2023. Drug Deliv. 30: 2174209. PMID: 36762548
- Andrographolide exerts anti-respiratory syncytial virus activity by up-regulating heme oxygenase-1 independent of interferon responses in human airway epithelial cells. | Che, S., et al. 2023. Mol Biol Rep. 50: 4261-4272. PMID: 36918433
- Chemosensitizing potential of andrographolide in P-glycoprotein overexpressing multidrug-resistant cancer cell lines. | Lakra, DS., et al. 2023. Nat Prod Res. 1-6. PMID: 37144420
- Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38/Nrf2/HO-1 pathway. | Li, W., et al. 2023. Arch Biochem Biophys. 742: 109622. PMID: 37172672
- Size-dependence of the skin penetration of andrographolide nanosuspensions: In vitro release-ex vivo permeation correlation and visualization of the delivery pathway. | Yao, S., et al. 2023. Int J Pharm. 641: 123065. PMID: 37225025
- Antidepressant evaluation of Andrographis paniculata Nees extract and andrographolide in chronic unpredictable stress zebrafish model. | Aldurrah, Z., et al. 2023. Comp Biochem Physiol C Toxicol Pharmacol. 271: 109678. PMID: 37301417
- HPTLC Stability Indicating Analytical Method of Andrographolide and 5-fluorouracil with Network Pharmacology Analysis against Cancer. | Malik, Z., et al. 2023. Comb Chem High Throughput Screen.. PMID: 37303181
- Utilizing Andrographis paniculata leaves and roots by effective usage of the bioactive andrographolide and its nanodelivery: investigation of antikindling and antioxidant activities through in silico and in vivo studies. | Baru Venkata, R., et al. 2023. Front Nutr. 10: 1185236. PMID: 37324729
- Identification of Andrographolide as a novel FABP4 inhibitor for osteoarthritis treatment. | Yang, K., et al. 2023. Phytomedicine. 118: 154939. PMID: 37354697
Inhibitor of:
β-defensin 2, β-defensin 33, 14-3-3 σ, ADAM26B, ADAM34, ADAM38, ADAM39, AP1, BACH1, C14orf148, C1r, C8α, CARD 14, CARD 6, CARD 8, CARD 9, CRISP-3, CTAP-III, ERK, galectin-9, gasdermin A2, gasdermin A3, Gram Negative Endotoxin Marker, GRO, GSTT4, H2-Dk, Hep B sAg, Hep B xAg, HHV-4 LMP-1, HIV vpr, HSCARG_NMRAL1, IκB-δ, IκB-ζ, IκB-pp40, ICEBERG, IER3IP1, IFIX, IFN-α9, IIGP, IKIP, IL-10Rα, IL-12B p70, IL-20, IL-23, Il-28a, IL-33, IL1R2, IRAK-2, KIAA0776, LBP1, LITAF, LURAP1L, MD-1, MD-2, METH-1, MGST1, Mill2, MIP-2α, MMP-20, MUP2, NAIP2, NAIP5, NAIP6, NAIP7, NALP13, NALP14, NALP1B, NALP4B, NALP4C, NALP5, NALP6, NALP9, NF kappa B, NF-1B, NF-1X, NFκB p50, NFκB p65, NFKBIL1, NFKBIL2, NKRF, Olfr970, p100, p8, Properdin, PSP94, RAP1, Reg IIIβ, RelA, RelB, RELL1, Retnlb, SAA2, Ser/Thr Protein Kinase, T6BP, TANK, TFII-I, THP, TICAM-2, TIMP-4, TLR10, TLR3, TNF-IP 1, TNF-R2, TNFβ, TRAF1, TRAF7, TRAFD1, Trav9d-1, TRIM30A, TRIM56, TSA-1, TWEAK, UGT1A10, UGT1A4, UGT2A2, UGT2B11, UGT2B15, UGT2B17, UGT2B36, UGT2B7, UGT3A1, V1RF1, V1RF3, and VSTM4.Activator of:
Act1, CD200R2, CD30, Chitotriosidase, Cyp4f13, Factor B, ferritin, FMO9, FucT-VI, GSTA3, GSTM4, GSTT2B, GSTT4, H2-Aa, Heme Oxygenase 3, HLA-DX, IκB-γ, IκB-pp40, IFN-α12, IFN-α4, IL-12Rβ1, IL-32, IRAK-M, KIR3DS1, KLRF2, Myozenin 2, NALP11, NALP8, NF-E2, NIK, NKRF, Oas1e, Oas1f, PD-L2, RDH10, T-cell receptor Vδ 1, TGR5, TIRAP, TMC5, Tollip, UGT1A1, UGT1A2, UGT1A7, UGT2A1, UGT2A3, ZBTB6, and ZNF346.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Andrographolide, 50 mg | sc-205594 | 50 mg | $15.00 | |||
Andrographolide, 100 mg | sc-205594A | 100 mg | $39.00 |